Home › Funds › BML Capital Management, LLC › ACRS

BML Capital Management, LLC position in ACRS

ACLARIS THERAPEUTICS INC · Health Care

BML Capital Management, LLC reported holding 10,955,000 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$57.6M, representing 30.71% of its reported portfolio and ranking #1 among its reported holdings. BML Capital Management, LLC has disclosed ACRS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)10.96M sh
Reported value held$57.62M
Portfolio Weight30.71%
First reportedQ4 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BML Capital Management, LLC's ACRS position evolved

BML Capital Management, LLC first disclosed a stake in ACRS in Q4 2023 at 653,107 shares (US$686K). The position peaked in Q2 2026 at 11,975,000 shares, worth US$63.3M. Across 12 filings, BML Capital Management, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 10,955,000 shares valued at US$57.6M — a reduction of -1,020,000 shares quarter over quarter.. Notable position changes include a 1339% increase in Q1 2024 (shares fell 11% over the following quarter), a 38% increase in Q2 2024 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 653.11K $685.76K New
Q1 2024 9.40M $11.65M Add
Q2 2024 12.99M $14.29M Add
Q3 2024 14.25M $16.39M Add
Q4 2024 14.25M $35.34M Hold
Q1 2025 14.25M $21.80M Hold
Q2 2025 14.25M $20.23M Hold
Q3 2025 14.25M $27.07M Hold
Q4 2025 14.25M $42.89M Hold
Q1 2026 14.25M $53.44M Hold
Q2 2026 11.97M $63.35M Reduce
Q3 2026 10.96M $57.62M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACRS and 13F data

ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), Deep Track Capital, LP (US$49.4M), Vivo Capital, LLC (US$35.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACRS

All ACRS fund holders →

FAQ

How long has BML Capital Management, LLC held ACRS?

BML Capital Management, LLC has disclosed ACRS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is BML Capital Management, LLC's current position in ACRS?

As of Q3 2026, BML Capital Management, LLC holds 10.96M shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $57.62M, representing 30.71% of its reported portfolio and ranking #1.

Has BML Capital Management, LLC been buying or selling ACRS?

In the latest 13F filing (Q3 2026), BML Capital Management, LLC reduced its position in ACRS. The position peaked in Q2 2026 at 11.97M shares.

Which other funds hold ACRS?

Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., Deep Track Capital, LP, Vivo Capital, LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.